Li Dean Y's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Nov 19, 2021
- Accession no.
- 0001209191-21-065896
- Filed
- Nov 19, 2021
- Trade date
- Nov 17-19, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $384.9K. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0001209191-21-068911 (Dec 9, 2021). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Li Dean YCIK 0001837016 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.13 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.
- F3
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.